SCHEMBL4873060

SCHEMBL4873060

O=[N+]([O-])c1ccc(-c2cc(-c3c(Cl)cccc3Cl)on2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR1 P25024 1/20 0.51
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
MAPT P10636 6/20 0.43
TDP1 Q9NUW8 2/20 0.43
MAPK1 P28482 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
POLB P06746 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
PKM P14618 1/20 0.42
MCL1 Q07820 1/20 0.42
CASP3 P42574 1/20 0.41
PSD A5PKW4 1/20 0.41
CA12 O43570 1/20 0.41
CA9 Q16790 1/20 0.41
APP P05067 1/20 0.41
CASP1 P29466 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4869280 0.88 NPC1 (0.50) NPC1RAB9AMAPTMAPK1MEN1
SCHEMBL17084384 0.80 NPC1 (0.67) CXCR1NPC1RAB9AMAPTMAPK1
SCHEMBL28689579 0.80 NPC1 (0.67) CXCR1NPC1RAB9AMAPTMAPK1
SCHEMBL22038596 0.77 CXCR1 (0.53) CXCR1NPC1RAB9AMAPTCASP3
SCHEMBL4868674 0.76 APP (0.44) NPC1RAB9AMAPTTDP1POLB
SCHEMBL4873946 0.74 APP (0.45) NPC1RAB9AMAPTTDP1POLB
SCHEMBL19403807 0.73 CXCR1 (0.50) CXCR1NPC1RAB9AMAPTTDP1
SCHEMBL17084386 0.73 CXCR1 (0.70) CXCR1NPC1RAB9AMAPTMAPK1
SCHEMBL4873827 0.73 MAPT (0.61) NPC1RAB9AMAPTPOLBMEN1
SCHEMBL16549592 0.72 RAB9A (0.54) CXCR1NPC1RAB9AMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7326790-B2 Diphenylisoxazole compounds and hydro isomers thereof RIGEL PHARMACEUTICALS, INC. (US) 2008-02-05 US disclosed
EP-1620412-A2 HETEROCYCLIC COMPOUNDS AND HYDRO ISOMERS THEREOF Rigel Pharmaceuticals, Inc. (US) 2006-02-01 EP disclosed
US-20040254227-A1 Heterocyclic compounds and hydro isomers thereof MIDCAP FINANCIAL TRUST 2004-12-16 US disclosed
WO-2004099165-A2 HETEROCYCLIC COMPOUNDS AND HYDRO ISOMERS THEREOF RIGEL PHARMACEUTICALS, INC. (US) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254227-A1 Heterocyclic compounds and hydro isomers thereof HAVCR2, PCNA, HCCS CXCR1 186/4885NPC1 703/4885RAB9A 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.